Cargando…

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes

To examine the prognostic value of claudin 18.2 (CLDN18.2) and human epidermal growth factor receptor-2 (HER-2) expression in patients with resected pancreatic ductal adenocarcinoma (PDAC). This study enrolled patients who underwent surgery and were diagnosed with PDAC at Suleyman Demirel University...

Descripción completa

Detalles Bibliográficos
Autores principales: Kayikcioglu, Erkan, Yüceer, Ramazan Oğuz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907975/
https://www.ncbi.nlm.nih.gov/pubmed/36820561
http://dx.doi.org/10.1097/MD.0000000000032882
_version_ 1784884286616240128
author Kayikcioglu, Erkan
Yüceer, Ramazan Oğuz
author_facet Kayikcioglu, Erkan
Yüceer, Ramazan Oğuz
author_sort Kayikcioglu, Erkan
collection PubMed
description To examine the prognostic value of claudin 18.2 (CLDN18.2) and human epidermal growth factor receptor-2 (HER-2) expression in patients with resected pancreatic ductal adenocarcinoma (PDAC). This study enrolled patients who underwent surgery and were diagnosed with PDAC at Suleyman Demirel University Hospital, Turkey between 2015 and 2019. Sixty-eight patients with resected PDAC treated at a medical oncology clinic were assessed. All patients were over the age of 18 years, underwent follow-up and treatment in our unit, and had pathology slides that we could access. Clinicopathological data were obtained from medical files, including the patients’ age, sex, pathological parameters, and clinical stage according to the Eighth International Union against Cancer/American Joint Committee on Cancer. Patient survival and the period from the date of diagnosis to death were assessed in the follow-up data. There was no statistically significant difference between CLDN18.2 and HER-2 expression scores for samples and patient clinicopathological characteristics. No HER-2 expression scores of ≥2 were found in the samples. Only 25% (n = 17) of the samples had HER-2 expression scores of +1. CLDN18.2 expression was detected in 54.4% (n = 37) of the patient samples. CLDN18.2 expression scores were +1 in 30.8% (n = 21) of the patient samples, +2 in 16.2% (n = 11), and +3 in 7.4% (n = 5). When CLDN18.2 and HER-2 expression were compared, a statistically significant difference and moderate positive correlation were observed. No significant relationship between HER-2 expression and survival was observed in the survival analysis of PDAC patients; however, high CLDN18.2 expression was related to longer overall survival. Our study is the third to research CLDN18.2 expression in PDAC. HER-2 expression is low and CLDN18.2 expression is high in patients with PDAC. HER-2 expression is not related to overall survival but CLDN18.2 is related and may be used as a prognostic marker in patients with PDAC.
format Online
Article
Text
id pubmed-9907975
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-99079752023-02-10 The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes Kayikcioglu, Erkan Yüceer, Ramazan Oğuz Medicine (Baltimore) 5700 To examine the prognostic value of claudin 18.2 (CLDN18.2) and human epidermal growth factor receptor-2 (HER-2) expression in patients with resected pancreatic ductal adenocarcinoma (PDAC). This study enrolled patients who underwent surgery and were diagnosed with PDAC at Suleyman Demirel University Hospital, Turkey between 2015 and 2019. Sixty-eight patients with resected PDAC treated at a medical oncology clinic were assessed. All patients were over the age of 18 years, underwent follow-up and treatment in our unit, and had pathology slides that we could access. Clinicopathological data were obtained from medical files, including the patients’ age, sex, pathological parameters, and clinical stage according to the Eighth International Union against Cancer/American Joint Committee on Cancer. Patient survival and the period from the date of diagnosis to death were assessed in the follow-up data. There was no statistically significant difference between CLDN18.2 and HER-2 expression scores for samples and patient clinicopathological characteristics. No HER-2 expression scores of ≥2 were found in the samples. Only 25% (n = 17) of the samples had HER-2 expression scores of +1. CLDN18.2 expression was detected in 54.4% (n = 37) of the patient samples. CLDN18.2 expression scores were +1 in 30.8% (n = 21) of the patient samples, +2 in 16.2% (n = 11), and +3 in 7.4% (n = 5). When CLDN18.2 and HER-2 expression were compared, a statistically significant difference and moderate positive correlation were observed. No significant relationship between HER-2 expression and survival was observed in the survival analysis of PDAC patients; however, high CLDN18.2 expression was related to longer overall survival. Our study is the third to research CLDN18.2 expression in PDAC. HER-2 expression is low and CLDN18.2 expression is high in patients with PDAC. HER-2 expression is not related to overall survival but CLDN18.2 is related and may be used as a prognostic marker in patients with PDAC. Lippincott Williams & Wilkins 2023-02-10 /pmc/articles/PMC9907975/ /pubmed/36820561 http://dx.doi.org/10.1097/MD.0000000000032882 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 5700
Kayikcioglu, Erkan
Yüceer, Ramazan Oğuz
The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
title The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
title_full The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
title_fullStr The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
title_full_unstemmed The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
title_short The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
title_sort role of claudin 18.2 and her-2 in pancreatic cancer outcomes
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907975/
https://www.ncbi.nlm.nih.gov/pubmed/36820561
http://dx.doi.org/10.1097/MD.0000000000032882
work_keys_str_mv AT kayikciogluerkan theroleofclaudin182andher2inpancreaticcanceroutcomes
AT yuceerramazanoguz theroleofclaudin182andher2inpancreaticcanceroutcomes
AT kayikciogluerkan roleofclaudin182andher2inpancreaticcanceroutcomes
AT yuceerramazanoguz roleofclaudin182andher2inpancreaticcanceroutcomes